Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Four-year COMBAT data detail benefits of Duodart in benign prostatic hyperplasia

May 4, 2010

Intraprostatic botulinum toxin type A improves signs and symptoms of BPH

April 30, 2010

Tanezumab shows benefit in patients with interstitial cystitis

April 23, 2010

Tacrolimus improves symptoms of bladder pain syndrome/interstitial cystitis

April 23, 2010

ONO-8539 for overactive bladder well tolerated in healthy adults

April 21, 2010

Mirabegron well tolerated and improves overactive bladder variables in large study

April 19, 2010

Clinical data disclosed on avosentan in overt diabetic nephropathy

April 14, 2010

Allergan and Serenity Pharmaceuticals to collaborate on development Ser-120 for nocturia

April 8, 2010

Nymox outlines new plans for phase III BPH drug NX-1207

April 7, 2010

GSK's Duodart approved for benign prostatic hyperplasia in E.U.

April 6, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...